Clinical Practice Guidelines for Improving Outcomes in Sepsis

Heart Lung and Circulation

Volumn 17, Issue SUPPL. 4, 2008, Pages

  Ihle, Benno U ^a  

^a EPWORTH HOSPITAL   (Australia)

Author keywords

EBM; Sepsis; Septic shock; Vasopressors

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; ANTIBIOTIC AGENT; DOBUTAMINE; DOPAMINE; FLUDROCORTISONE; HYDROCORTISONE; HYPERTENSIVE FACTOR; PHENYLEPHRINE; STEROID; TERLIPRESSIN;

ALGORITHM; ARTICLE; CLINICAL TRIAL; DEATH; EVIDENCE BASED PRACTICE; HUMAN; INFECTION; INFLAMMATION; LOW DRUG DOSE; MEDICAL EXPERT; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPSIS; SYMPTOM;

ALGORITHMS; HUMANS; PRACTICE GUIDELINES AS TOPIC; SEPSIS;

EID: 56949103490     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2008.08.005     Document Type: Article

References (30)

1. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Eng J Med 348 (2003) 1546-1554
2. Finfer S., Bellomo R., Lipman J., French C., Dobb G., and Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 30 (2004) 589-596
3. Salvo I., de Cain W., Musicco M., Langer M., Piadena R., Wolfer A., Montani C., and Magni E. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21 Suppl 2 (1995) S244-S249
4. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United Sates: analysis of incidence, outcomes, and associated cost of care. Crit Care Med 29 (2001) 1303-1310
5. Brun-Buisson C., Doyon F., Carlet J., Dellamonica P., Gouin F., Lepoutre A., Mercier J.C., Offenstadt G., and Regnier B. Incidence, risk factors, and outcomes of severe sepsis and septic shock in adults. A multi-center prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 274 (1995) 968-974
6. Padkin A., Goldfrad C., Brady A., Young D., Black N., and Rowan K. Epidemiology of severe sepsis occurring in the first 24 h in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 31 (2003) 2332-2338
7. Pittet D., Rangel-Frausto S., Li N., Tarara D., Costigan M., Rempe L., Jebson P., and Wenzel R.P. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 21 (1995) 302-309
8. The Australian Resuscitation in Sepsis (ARISE) investigators and the Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database (APD) Management Committee. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resuscitation 2007;9:8-18.
9. Gao F., Melody T., Daniels D.F., Giles S., and Fox S. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis-prospective observational study. Crit Care 9 (2005) R764-R770
10. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., Reinhart K., Angus D.C., Brun-Buisson C., Beale R., Calandra T., Dhainaut J.-F., Gerlach H., Harvey M., Marini J.J., Marshall J., Ranieri M., Ramsay G., Sevransky J., Thompson T., Townsend S., Vender J.S., Zimmerman J.L., and Vincent J.-L. For the International Surviving Sepsis Campaign Guidelines Committee. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med 36 (2008) 296-327
11. Bernard G.R., Vincent J.L., Laterre P.F., La-Rosa S.P., Dhainaut J.F., Lopeez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., and Fisher Jr. C.J. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. N Eng J Med 344 10 (2001) 699-709
12. Rivers E., Nguyen B., Havstad F., Ressler J., Muzzin A., Knoblich B., Peterson E., and Tomnalovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Eng J Med 345 (2001) 1368-1377
13. Guyatt G., Vist G., Falck-Ytter Y., Kunz R., Magrini N., and Schunemann H. An emerging consensus on grading recommendations?. Evid Based Med 11 (2006) 2-4
14. GRADE working group: Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-8.
15. Guyatt G., Gutterman D., Baumann M.H., Addrizzo-Harris D., Hylek E.M., Phillips B., Raskob G., and Lewis S.Z. Grading strength of recommendations and quality of evidence in clinical guidelines: report from American College of Chest Physicians task force. Chest 129 (2006) 174-181
16. Russell J.A., Walley K.R., Singer J., Gordon A.C., Hebert P.C., Cooper J.D., Holmes C.L., Mehta S., Granton J.T., Storms M.M., Cook D.J., and Presneill J.J. Ayers D for the VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Eng J Med 358 (2008) 877-887
17. Dunser M.W., Mayr A.J., Ulmer H., Knotzer H., Sumann G., Pajk W., Friesenecker B., and Hasibeder Wr. Arginine vasopressin in advanced vasodilator shock: A prospective, randomized controlled study. Circulation 107 (2003) 2313-2319
18. Sharshar T., Blanchard A., Paillard M., Raphael J.C., Gajdos P., and Ananne D. Circulating vasopressin levels in septi shock. Crit Care Med 31 (2003) 1752-1758
19. Bellomo R., Chapman M., Finfer S., Hickling K., and Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. ANZICS CTG. Lancet 356 (2000) 2139-2143
20. Pinsky M.R., and Payen D. Functional hemodynamic monitoring. Crit Care 9 (2005) 566-572
21. Myburgh J.A., Higgins A., and Jovanovska A. A comparison of epinephrine and norepinephrine on reversal of shock. Intensive Care Med 33 (2007) S197
22. Blot F., Schmidt E., Nitenberg G., Tancrede C., Ledercq B., Laplanche A., and Andremond A. Earlier positivity of central venous versus peripheral blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol 36 (1998) 105-109
23. Kumar A., Roberts D., Wood K.E., Light B., Parrillo J.E., Sharma S., Suppes R., Feinstein D., Zanotti S., Talberg L., Gurka D., Kumar A., and Cheang M. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 (2006) 1589-1596
24. Sprung C.L., Annane D., Keh D., Moreno R., Singer M., Freivogel K., Weiss Y.G., Benbenishty J., Kalenka A., Forst H., Laterre P.F., Reinhardt K., Cuthbertson B.H., Payen D., and Briegel J. For the CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Eng J Med 358 (2008) 111-124
25. Annane D., Sebille V., Charpentier C., Bollaert P.E., Francois B., Korach J.M., Capellier G., Cohen Y., Azoulay E., Troche G., Chaumet-Riffaut P., and Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
26. Briegel J., Forst H., Haller M., Schelling G., Kilger E., Kuprat G., Hemmer B., Hummel T., Lenhart A., Heyduck M., Stoll C., and Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-centre-study. Crit Care Med 27 (1999) 723-732
27. Bollaert P.E., Charpentier C., Levy B., Debouverie M., Audibert G., and Larcan A. Reversal of late septic shock with supra-physiological doses of hydrocortisone. Crit Care Med 26 (1998) 645-650
28. Briegel J., Vogeser M., and Annane D. Measurement of cortisol in septic shock: interlaboratory harmonization. Am Rev Respir Crit Care 175 (2007) A436
29. Abraham E., Laterre P.F., Garg R., Levy H., Talwar D., Trzaskoma B.L., Francois B., Guy J.S., Bruckmann M., Rea-Neto A., Rossaint R., Perrotin D., Sablotski A., Arkins N., Utterback B.G., and Macias W.L. For the Administration of Drotecogin Alfa(Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. N Eng J Med 353 (2005) 1332-1341
30. European Medicine Agency; Evaluation of Medicines for Human Use. http://www.emea.europa.eu/pdfs/human/press/pr/8509607en.pdf.